Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study December 16, 2019 • 3:15 PM EST
Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL December 11, 2019 • 4:05 PM EST
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia December 10, 2019 • 7:00 AM EST
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement December 3, 2019 • 7:00 AM EST
Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD November 26, 2019 • 4:05 PM EST
Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference November 25, 2019 • 4:05 PM EST
Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia November 21, 2019 • 8:00 AM EST
Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder November 20, 2019 • 4:05 PM EST
Tonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering November 20, 2019 • 7:00 AM EST
